Chronic Hepatitis B Infection: New Approaches towards Cure
暂无分享,去创建一个
N. Osna | M. Ganesan | Benson J. Edagwa | L. Poluektova | Srijanee Das | M. Ogunnaike | Ashrafi Sultana | Mohammad Ullah Nayan | Samiksha S. Raut
[1] T. Asselah,et al. Hepatitis D Virus Infection. , 2023, The New England journal of medicine.
[2] Yang Zhang,et al. Discovery, optimization and biological evaluation of novel HBsAg production inhibitors. , 2023, European journal of medicinal chemistry.
[3] Yao-Chun Hsu,et al. Global burden of hepatitis B virus: current status, missed opportunities and a call for action , 2023, Nature Reviews Gastroenterology & Hepatology.
[4] S. Oka,et al. Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men , 2023, Hepatology.
[5] Wenhai Huang,et al. The progress of molecules and strategies for the treatment of HBV infection , 2023, Frontiers in Cellular and Infection Microbiology.
[6] V. Soriano,et al. Susceptibility to hepatitis B virus infection in adults living in Spain , 2023, Liver international : official journal of the International Association for the Study of the Liver.
[7] H. Cheng,et al. Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B , 2023, Medicine.
[8] A. Lok,et al. The scientific basis of combination therapy for chronic hepatitis B functional cure , 2023, Nature Reviews Gastroenterology & Hepatology.
[9] C. la Vecchia,et al. Cancers attributable to infectious agents in Italy. , 2023, European journal of cancer.
[10] F. Zoulim,et al. Eliminating cccDNA to cure Hepatitis B virus (HBV) infection. , 2023, Journal of hepatology.
[11] H. Gendelman,et al. An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression , 2022, Science advances.
[12] J. Young,et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. , 2022, Journal of hepatology.
[13] D. Thomas,et al. Long-Acting Treatments for Hepatitis B. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] T. Asselah,et al. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. , 2022, The New England journal of medicine.
[15] Chien-Jen Chen,et al. Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status , 2022, JHEP reports : innovation in hepatology.
[16] M. Brunetto,et al. Highly dynamic changes of regional HBV epidemiology over two decades. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[17] H. Günthard,et al. HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Paik. Lenacapavir: First Approval , 2022, Drugs.
[19] T. Taddei,et al. Attacking the public health crisis of hepatocellular carcinoma at its roots , 2022, Hepatology.
[20] H. Razavi,et al. The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road , 2022, Journal of Hepatology.
[21] H. Gendelman,et al. Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. , 2022, Future microbiology.
[22] Lalu Muhammad Irham,et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The lancet. Gastroenterology & hepatology.
[23] Juan Chen,et al. SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters , 2022, Frontiers in Microbiology.
[24] Meghan M. Holdorf,et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] P. Mangeot,et al. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants , 2022, mBio.
[26] Noele P. Nelson,et al. Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[27] S. Delany-Moretlwe,et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial , 2022, The Lancet.
[28] C. Steer,et al. Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing , 2022, Hepatology communications.
[29] Ciaran M. Lee,et al. Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes , 2022, The CRISPR journal.
[30] H. Torres,et al. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[31] M. Yuen,et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection , 2022, Clinical and molecular hepatology.
[32] H. Karimi-Sari,et al. Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg) , 2022, Journal of clinical medicine.
[33] P. Venkatesan. Long-acting injectable ART for HIV: a (cautious) step forward. , 2022, The Lancet. Microbe.
[34] G. Papatheodoridis,et al. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis , 2022, Journal of gastroenterology and hepatology.
[35] M. Baum,et al. CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women , 2022, BMJ Open.
[36] R. Weiskirchen,et al. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases , 2021, Frontiers in Pharmacology.
[37] Chun‐Xia Zhao,et al. Lipid Nanoparticles for Drug Delivery , 2021, Advanced NanoBiomed Research.
[38] H. Hsiao,et al. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation , 2021, Journal of personalized medicine.
[39] H. Gendelman,et al. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles , 2021, Nature Communications.
[40] M. Yuen,et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study , 2021, JHEP reports : innovation in hepatology.
[41] Yue Chen,et al. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. , 2021, Clinics and research in hepatology and gastroenterology.
[42] Shaoman Yin,et al. Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018. , 2021, Hepatology.
[43] M. Iannacone,et al. Immunobiology and pathogenesis of hepatitis B virus infection , 2021, Nature Reviews Immunology.
[44] W. Jiskoot,et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability , 2021, International Journal of Pharmaceutics.
[45] Danping Huang,et al. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy , 2021, World journal of gastroenterology.
[46] Anh-Hoa Nguyen,et al. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B , 2021, Hepatology.
[47] Juan Li,et al. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] Zongguo Yang,et al. Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis , 2021, Bioengineered.
[49] Y. Chong,et al. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[50] D. Venzon,et al. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. , 2020, Journal of hepatology.
[51] Yan Huang,et al. Editorial: tenofovir alafenamide fumarate—a new bullet to prevent mother‐to‐child transmission of hepatitis B virus. Authors' reply , 2020, Alimentary pharmacology & therapeutics.
[52] J. Sagartz,et al. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice , 2020, Molecular therapy. Methods & clinical development.
[53] M. Motamedi,et al. Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis , 2020, Frontiers in Pharmacology.
[54] A. van der Straten,et al. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP) , 2020, Pharmaceutics.
[55] Gene W. Yeo,et al. Base editing: advances and therapeutic opportunities , 2020, Nature Reviews Drug Discovery.
[56] V. Soriano,et al. Advances in hepatitis B therapeutics , 2020, Therapeutic advances in infectious disease.
[57] J. Borghi,et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.
[58] A. Lok,et al. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients , 2020, Clinical and translational gastroenterology.
[59] J. Niu,et al. Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[60] J. McMillan,et al. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research , 2020, Expert opinion on drug delivery.
[61] A. Markham. Cabotegravir Plus Rilpivirine: First Approval , 2020, Drugs.
[62] Y. Lim,et al. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[63] M. Peet,et al. Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats. , 2020, International journal of pharmaceutics.
[64] Jonathan T. Su,et al. Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate , 2020, Pharmaceutical Research.
[65] H. Gendelman,et al. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. , 2020, Nanomedicine : nanotechnology, biology, and medicine.
[66] Ding‐Shinn Chen,et al. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing , 2020, Molecular therapy. Nucleic acids.
[67] G. Dusheiko. Will we need novel combinations to cure HBV infection? , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[68] Trushar R. Patel,et al. Host Transcription Factors in Hepatitis B Virus RNA Synthesis , 2020, Viruses.
[69] Qinghua Zhou,et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer , 2020, Medicine.
[70] M. Manoharan,et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs , 2019, Nature Nanotechnology.
[71] D. Castor,et al. The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment , 2019, Current opinion in HIV and AIDS.
[72] M. Buti,et al. Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference , 2019, Hepatology.
[73] H. Gendelman,et al. Synthesis of a long acting nanoformulated emtricitabine ProTide. , 2019, Biomaterials.
[74] F. Zoulim,et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial , 2019, Human vaccines & immunotherapeutics.
[75] M. Maini,et al. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B , 2019, Nature Reviews Gastroenterology & Hepatology.
[76] H. Gendelman,et al. A long acting nanoformulated lamivudine ProTide. , 2019, Biomaterials.
[77] F. Zoulim,et al. Therapeutic strategies for hepatitis B virus infection: towards a cure , 2019, Nature Reviews Drug Discovery.
[78] F. Lu,et al. [Exosome-mediated CRISPR/Cas9 system targets to cut the intercellular transmission function of hepatitis B virus genome]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
[79] Seth P. Forster,et al. Exploration of long-acting implant formulations of hepatitis B drug entecavir. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[80] H. Gendelman,et al. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation , 2019, International journal of nanomedicine.
[81] A. van der Straten,et al. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP) , 2019, Pharmaceutics.
[82] A. Mangia,et al. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. , 2019, Gastroenterology.
[83] Y. Huang,et al. Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B , 2019, Journal of viral hepatitis.
[84] J. Sasadeusz,et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement , 2019, The Medical journal of Australia.
[85] P. Easterbrook,et al. Hepatitis B virus infection in children and adolescents. , 2019, The lancet. Gastroenterology & hepatology.
[86] C. Gersbach,et al. The next generation of CRISPR–Cas technologies and applications , 2019, Nature Reviews Molecular Cell Biology.
[87] Zeyu Zhang,et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis , 2019, BMC cancer.
[88] W. Talloen,et al. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. , 2019, Gastroenterology.
[89] G. Doncel,et al. Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV , 2019, Pharmaceutics.
[90] Md. Sohel Rana,et al. Interest of Youth Living With HIV in Long-Acting Antiretrovirals , 2019, Journal of acquired immune deficiency syndromes.
[91] M. Buti,et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2019, Gastroenterology.
[92] Maocai Yan,et al. Entecavir‐loaded poly (lactic‐co‐glycolic acid) microspheres for long‐term therapy of chronic hepatitis‐B: Preparation and in vitro and in vivo evaluation , 2019, International journal of pharmaceutics.
[93] P. Prathipati,et al. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[94] Q. Bian,et al. Real‐world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load , 2018, Alimentary pharmacology & therapeutics.
[95] S. Bao,et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk , 2018, Expert opinion on biological therapy.
[96] Y. Choi,et al. Design and in vivo evaluation of entecavir‐3‐palmitate microcrystals for subcutaneous sustained delivery , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[97] R. L. Hood,et al. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre‐exposure prophylaxis , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[98] A. Bradley,et al. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements , 2018, Nature Biotechnology.
[99] A. Collier,et al. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. , 2018, Journal of pharmaceutical sciences.
[100] G. Doncel,et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women , 2018, PloS one.
[101] A. Mangia,et al. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. , 2018, Gastroenterology.
[102] A. Ely,et al. Gene Therapy for Chronic HBV—Can We Eliminate cccDNA? , 2018, Genes.
[103] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[104] F. Zoulim,et al. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[105] G. V. van Westen,et al. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP , 2017, Scientific Reports.
[106] Anh-Hoa Nguyen,et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. , 2017, Journal of hepatology.
[107] Wenzhe Lu,et al. A novel orally available small molecule that inhibits hepatitis B virus expression. , 2017, Journal of hepatology.
[108] Thomas Berg,et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.
[109] G. Lauer,et al. Hepatitis B virus infection and the immune response: The big questions. , 2017, Best practice & research. Clinical gastroenterology.
[110] Yu-Hua Li,et al. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis , 2017, Clinical and Experimental Medicine.
[111] A. Collier,et al. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma , 2017, AIDS.
[112] R. Guner,et al. Adverse effects of oral antiviral therapy in chronic hepatitis B , 2017, World journal of hepatology.
[113] David R. Liu,et al. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.
[114] Yan Zhou,et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. , 2016, Gastroenterology.
[115] W. Haefeli,et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. , 2016, Journal of hepatology.
[116] H. Gendelman,et al. Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine , 2016, Journal of acquired immune deficiency syndromes.
[117] J. Jia,et al. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B , 2016, International journal of environmental research and public health.
[118] Shuqin Zhang,et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.
[119] K. Jerome,et al. Genome editing and the next generation of antiviral therapy , 2016, Human Genetics.
[120] Huiyan Zhang,et al. Changing etiologies and outcome of liver failure in Southwest China , 2016, Virology Journal.
[121] F. Zoulim,et al. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. , 2016, Journal of hepatology.
[122] Erica B. Schlesinger,et al. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis , 2016, Pharmaceutical Research.
[123] Fares Alahdab,et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.
[124] T. Therneau,et al. Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.
[125] Z. Goodman,et al. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B , 2015, Advances in Therapy.
[126] A. Ely,et al. Progress and Prospects of Anti-HBV Gene Therapy Development , 2015, International journal of molecular sciences.
[127] Mark Taylor,et al. NICE CG178 Psychosis and Schizophrenia in Adults: Treatment and Management – an evidence-based guideline? , 2015, British Journal of Psychiatry.
[128] Thomas J. Smith,et al. Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis , 2015, Antimicrobial Agents and Chemotherapy.
[129] N. Kootstra,et al. O114 : Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA , 2015 .
[130] B. Autran,et al. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.
[131] A. Sher,et al. Type I interferons in infectious disease , 2015, Nature Reviews Immunology.
[132] Luis Menéndez-Arias,et al. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. , 2014, Current opinion in virology.
[133] Daesik Kim,et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.
[134] H. Kim,et al. A guide to genome engineering with programmable nucleases , 2014, Nature Reviews Genetics.
[135] N. Shelke,et al. Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy , 2014, PloS one.
[136] Zhenghong Yuan,et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[137] R. Fontana,et al. Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B , 2013, Alimentary pharmacology & therapeutics.
[138] Yoshiyuki Suzuki,et al. Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.
[139] U. Haberkorn,et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts , 2013, Hepatology.
[140] P. Lampertico,et al. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history , 2013, Expert review of anti-infective therapy.
[141] G. Doncel,et al. A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis , 2012, Antimicrobial Agents and Chemotherapy.
[142] M. Levrero,et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.
[143] Qiang Deng,et al. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. , 2011, Journal of hepatology.
[144] Thuy D. Vo,et al. Transient cold shock enhances zinc-finger nuclease–mediated gene disruption , 2010, Nature Methods.
[145] F. Negro. Adverse effects of drugs in the treatment of viral hepatitis. , 2010, Best practice & research. Clinical gastroenterology.
[146] F. Zoulim,et al. Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.
[147] R. Perrillo. Benefits and risks of interferon therapy for hepatitis B , 2009, Hepatology.
[148] J. Dienstag. Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.
[149] M. Yuen,et al. Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.
[150] F. Chisari,et al. Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[151] Leaf Huang. LPD Nanoparticles for Gene Delivery , 1999, Nature Biotechnology.
[152] M. Heikenwalder,et al. PASylated interferon &agr; efficiently suppresses hepatitis B virus and induces anti‐HBs seroconversion in HBV‐transgenic mice , 2019, Antiviral research.
[153] C. Sirlin,et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis , 2017, Abdominal Radiology.
[154] S. Locarnini,et al. Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus. , 2016, Cold Spring Harbor perspectives in medicine.
[155] Jennifer P. Freeling,et al. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. , 2015, AIDS research and human retroviruses.